Israeli cancer diagnostics startup SpoititEarly launched in the U.S. It is developing a test that uses AI and trained canines to analyze patients’ breath samples, with the goal of detecting cancer at its earliest stages. The company plans to begin selling the at-home test to U.S. consumers next year.

Emrelis, an antibody drug conjugate developed by AbbVie, is now FDA approved for patients whose non-small cell lung cancer overexpresses the protein c-Met. The pharma company said this ADC is its first internally developed solid tumor medicine as well as its first solid tumor FDA approval in lung cancer.

Despite what some may claim, AI will never replace doctors — but we could use AI to help improve the overall scaffolding that healthcare reimbursement runs on, decreasing costs and freeing up spending to focus on expenses directly tied to patient care activities.

To prepare for an autonomous surgical future, medtech leaders should explore the practical implications of potential scenarios, and structure investment accordingly. The key is to develop a living roadmap that drives decisions on a day-by-day basis, drawing on macro- and micro-trends.

Robert F. Kennedy Jr. testified before the House Committee on Appropriations and the Senate Health, Education, Labor and Pensions Committee on Wednesday. He faced questions on vaccines, HHS cuts and other issues.

Cohere Health raked in $90 million in Series C capital, taking its total funding to date to $200 million. This round of funding cements Cohere as the emerging winner in the prior authorization tech category, according to Michael Greeley, general partner at Flare Capital Partners.